Galenica AG (GALE) AI Stock Analysis

• Market Cap: CHF4.65B
• Dividend Yield: 2.46%
• Average Volume (3M): 91.35K
• Price to Earnings (P/E): 24.2
• Beta (1Y): 0.31
• Revenue Growth: 5.84%
• EPS Growth: 8.57%
• Country: CH
• Employees: 4,511
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 1.81
• Shares Outstanding: 50,000,000
• 10 Day Avg. Volume: 70,861
• 30 Day Avg. Volume: 91,351
• PEG Ratio: -0.57
• Price to Book (P/B): 2.39
• Price to Sales (P/S): 0.95
• P/FCF Ratio: 19.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF85.00
• Price Target Upside: -8.99% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: CHF95.00 ▲(1.71% Upside)

Galenica AG's strong financial performance and fair valuation are the primary drivers of its stock score. The technical analysis suggests a neutral market sentiment, with no significant bullish or bearish signals. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Profitability Margins

Strong profitability margins reflect efficient operations and cost control, supporting sustained earnings and competitive positioning.

Leverage Position

Improved leverage position enhances financial flexibility and reduces risk, supporting long-term growth and investment capacity.

Negative Factors

Operational Efficiency

Operational inefficiencies can limit profitability and growth potential, necessitating strategic improvements to maintain competitiveness.

Cash Conversion

Suboptimal cash conversion can constrain liquidity and reinvestment capabilities, impacting long-term financial health and shareholder returns.

EBIT Margin Pressure

Declining EBIT margins may signal rising costs or pricing pressures, potentially affecting profitability and competitive advantage.

Galenica AG Business Overview & Revenue Model

Company Description

Galenica AG (GALE) is a leading Swiss healthcare company specializing in the distribution and retail of pharmaceuticals, healthcare products, and services. The company operates primarily in two main sectors: the wholesale and retail of pharmaceuticals through its extensive pharmacy network, and the provision of healthcare services. Galenica's core products include prescription and over-the-counter medications, as well as a wide range of health and wellness products. The company is dedicated to enhancing patient care and ensuring the accessibility of healthcare solutions across Switzerland.

How the Company Makes Money

Galenica AG generates revenue primarily through its wholesale and retail operations. The wholesale division supplies pharmacies, hospitals, and other healthcare institutions with pharmaceuticals and healthcare products, earning income from the distribution of these goods. The retail segment, which includes its network of pharmacies, generates revenue from the sale of prescription medications and health-related products directly to consumers. Additionally, Galenica benefits from healthcare services, such as medication management and consultation services, which contribute to its earnings. Strategic partnerships with pharmaceutical manufacturers and healthcare providers enhance its product offerings and market reach, further solidifying its revenue streams.

Galenica AG Financial Statement Overview

Summary

Galenica AG exhibits a strong financial position with consistent revenue growth and solid profitability margins. The company maintains a strong equity base and has improved its leverage position. However, there is room for improvement in operational efficiency and cash conversion.

Income Statement

Galenica AG has demonstrated solid revenue growth over the years, with a notable increase in gross profit margin. The net profit margin is healthy, indicating effective cost management. However, the slight decline in EBIT margin suggests some pressure on operational efficiency.

Balance Sheet

The company maintains a strong equity base with a favorable equity ratio, reflecting financial stability. The reduction in total debt over time has improved the debt-to-equity ratio, enhancing the company's leverage position. Continued improvement in ROE highlights effective utilization of equity.

Cash Flow

Solid operating cash flow generation supports the company's liquidity. The free cash flow growth is commendable, supporting potential reinvestment and shareholder returns. However, the free cash flow to net income ratio indicates room for improvement in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.02B	3.92B	3.75B	4.01B	3.83B	3.48B
Gross Profit	391.10M	1.09B	387.60M	374.13M	350.55M	349.41M
EBITDA	340.46M	331.31M	306.92M	290.46M	300.33M	302.78M
Net Income	192.34M	182.95M	173.60M	165.13M	167.68M	172.25M
Balance Sheet
Total Assets	3.06B	3.07B	2.99B	2.66B	2.62B	2.26B
Cash, Cash Equivalents and Short-Term Investments	67.07M	129.68M	116.16M	93.93M	164.98M	59.78M
Total Debt	862.41M	775.60M	236.04M	686.49M	672.65M	640.63M
Total Liabilities	1.62B	1.52B	1.52B	1.41B	1.38B	1.21B
Stockholders Equity	1.44B	1.55B	1.47B	1.25B	1.23B	1.05B
Cash Flow
Free Cash Flow	298.18M	192.34M	149.34M	166.51M	273.02M	168.67M
Operating Cash Flow	329.81M	264.70M	225.71M	236.87M	333.10M	224.36M
Investing Cash Flow	-154.48M	-151.08M	-124.17M	-130.62M	-88.34M	-115.84M
Financing Cash Flow	-177.76M	-100.22M	-79.05M	-177.21M	-139.53M	-139.30M

Galenica AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 93.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALE, the sentiment is Positive. The current price of 93.4 is above the 20-day moving average (MA) of 90.50, above the 50-day MA of 88.97, and above the 200-day MA of 85.68, indicating a bullish trend. The MACD of 1.21 indicates Negative momentum. The RSI at 73.03 is Negative, neither overbought nor oversold. The STOCH value of 65.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:GALE.

Galenica AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOVE	71 Outperform	CHF3.02B	33.67	23.83%	0.46%	16.59%	65.76%
GALE	70 Outperform	CHF4.65B	24.21	―	2.46%	5.84%	8.57%
YPSN	70 Outperform	CHF4.33B	22.33	27.15%	0.69%	27.63%	160.67%
BANB	64 Neutral	CHF3.99B	29.70	10.07%	1.60%	17.34%	18.15%
SFZN	63 Neutral	CHF3.30B	20.77	15.79%	0.52%	0.77%	16.70%
TECN	62 Neutral	CHF1.62B	25.52	4.57%	2.37%	-9.34%	-37.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Galenica AG Corporate Events

Galenica AG Reports Robust Q3 Growth and Raises Guidance

Galenica AG reported a 4.7% increase in sales to CHF 2,999.7 million by the third quarter of 2025, driven by prescription drugs and nutritional supplements. The acquisition of Labor Team is expected to boost sales growth to between 4% and 6% and EBIT1 increase to between 10% and 12%. Despite a competitive consumer healthcare market, Galenica has maintained its market position, with significant contributions from its ‘Products & Care’ and ‘Logistics & IT’ segments.

The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF93.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.

Galenica AG Unveils Innovative Pharmacy Concept to Enhance Healthcare Services

Galenica AG is launching a new pharmacy concept at the Amavita pharmacy in Glattzentrum Zurich, aimed at enhancing customer experience and consultation services. This initiative is part of Galenica’s strategy to integrate digital and physical services, addressing changing customer needs and positioning pharmacies as central healthcare hubs. The pilot project will provide insights for future expansions, with further implementations planned for 2026.

The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF93.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.

Galenica AG Expands into Diagnostics with Labor Team Acquisition

Galenica AG has completed the acquisition of Labor Team, a leading Swiss diagnostic service provider, marking its entry into the diagnostics business. This strategic move will expand Galenica’s health network by integrating innovative laboratory services, strengthening its market position and enhancing healthcare offerings in Switzerland.

The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF92.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.

Galenica AG Reports Strong Half-Year Results, Raises EBIT Outlook

Galenica AG reported a 5.0% increase in sales to CHF 1,995.4 million for the first half of 2025, with adjusted EBIT rising by 10.9% to CHF 109.9 million. The company has raised its EBIT growth outlook to between 7% and 9%, driven by strong demand for prescription drugs and positive special effects. This performance positions Galenica slightly ahead of the broader pharmaceutical and consumer healthcare markets, indicating a robust operational footing and promising future prospects.

The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF89.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.